TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02049957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Sapnisertib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane tablets.
Study: NCT04187651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich plasma
Description: platelet rich plasma prepared from the patients' own blood will be applied to the fistula tract
Study: NCT04101825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auralya
Description: Hyaluronic Acid-Dermal Filler
Study: NCT02236195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat
Study: NCT02468544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
Study: NCT03283228

Intervention type: DIAGNOSTIC_TEST
Intervention: Cd11b and Cd56 markers
Description: The expression of CD11b and CD56 in newly diadnosed cases of AML

Intervention type: DIAGNOSTIC_TEST
Intervention: Cd11b and Cd56 markers
Description: The expression of CD11b and CD56 in newly diadnosed cases of AML
Study: NCT04334161

Intervention type: COMBINATION_PRODUCT
Intervention: Administration of glucose and controlled induction of hypoglycaemia.
Description: Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.

Intervention type: COMBINATION_PRODUCT
Intervention: Administration of glucose and controlled induction of hypoglycaemia.
Description: Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.

Intervention type: COMBINATION_PRODUCT
Intervention: Administration of glucose and controlled induction of hypoglycaemia.
Description: Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.

Intervention type: COMBINATION_PRODUCT
Intervention: Administration of glucose and controlled induction of hypoglycaemia.
Description: Functional metabolic test involving a 15g oral glucose load (enriched with 1.5% U-13C glucose) and subsequent controlled 20min hypoglycaemic clamp period. Neuroendocrine response will be assessed using frequent blood samples for hormones and metabolites, continuous heart rate monitoring and evaluation for hypoglycaemic symptoms.
Study: NCT03583333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMI/REL FDC
Description: 500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PIP/TAZ FDC
Description: 4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Open-label 600 mg Linezolid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Open-label 600 mg Linezolid
Study: NCT03735745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 30cc of blood will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 30cc of blood will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 30cc of blood will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 30cc of blood will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: 30cc of blood will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: 5cc of saliva will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: 5cc of saliva will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: 5cc of saliva will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: 5cc of saliva will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: 5cc of saliva will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Up to 10mg of tissue will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Up to 10mg of tissue will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Up to 10mg of tissue will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Up to 10mg of tissue will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Up to 10mg of tissue will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
Study: NCT02382393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Performance Test (BPT, Lumos Labs, Inc)
Description: A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain Performance Test (BPT, Lumos Labs, Inc)
Description: A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Assessment
Description: a validated, computerized cognitive assessment tool
Study: NCT02022657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Truvada
Description: Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
Study: NCT02382393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Assessment
Description: a validated, computerized cognitive assessment tool
Study: NCT01911767

Intervention type: DRUG
Intervention: Dimethyl fumarate
Description: Administered as specified in treatment arm.

Intervention type: DRUG
Intervention: Peginterferon beta-1a
Description: Administered as specified in treatment arm.
Study: NCT02479672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngoscopy
Description: Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Inline Stabilization
Description: Manual immobilization of Patient's neck with intention to minimize movement from baseline position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Inline Stabilization
Description: Manual immobilization of Patient's neck with intention to minimize movement from baseline position

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VividTrac®
Study: NCT01663324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS intervention 1
Description: Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS
Study: NCT00741650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Peer advisor
Description: Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, peer advisor and fast referral
Description: Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,
Study: NCT02018588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tryptophan
Description: graded levels of tryptophan will be given to each subject
Study: NCT01962805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex Formulation A
Study: NCT03735745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys
Description: The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
Study: NCT01962805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex Formulation A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex Formulation B
Study: NCT04587219

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Description: combined vector vaccine, 0,5ml/dose+0,5 ml/dose prime-boost immunization in days 1 (component I rAd26-S) and 21(component II rAd5-S)
Study: NCT01837602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cMet RNA CAR T cells
Study: NCT01953224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-based intervention
Description: Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study: NCT03789734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLS-M22
Description: BLS-M22 250mg/capsule
Study: NCT01663324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS intervention 2
Description: Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS
Study: NCT03789734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLS-M22
Description: BLS-M22 250mg/capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLS-M22
Description: BLS-M22 250mg/capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLS-M22
Description: BLS-M22 250mg/capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BLS-M22 placebo 250mg/capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BLS-M22 placebo 250mg/capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BLS-M22 placebo 250mg/capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BLS-M22 placebo 250mg/capsule
Study: NCT00651859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% Ophthalmic Solution
Description: Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% Ophthalmic Solution
Description: Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimatoprost Vehicle Ophthalmic Solution
Description: Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study: NCT01962805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex Formulation B
Study: NCT02966990

Intervention type: DEVICE
Group type: OTHER
Intervention: Hand Orthotic Devices
Description: Orthotic device made to provide the patient with better hand function
Study: NCT04358380

Intervention type: OTHER
Intervention: Liver injury
Description: LFTs elevation or liver decompensation
Study: NCT01533025

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: single bundle anterior cruciate ligament reconstruction with Achilles allograft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: single bundle anterior cruciate ligament reconstruction with Achilles allograft
Study: NCT02518750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal vincristine
Description: For intravenous (IV) use only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-asparaginase
Description: Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given by IV push over 3 to 5 seconds. For IV use only.
Study: NCT02142517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duct to mucosa PJ group
Description: Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invagination PJ group
Description: Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
Study: NCT00895752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
Study: NCT00001721

Intervention type: DRUG
Intervention: Cholesterol Suspension
Study: NCT01892787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Study: NCT02511483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol PO
Description: 20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV-PCA morphine
Description: Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA morphine
Description: Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Placebo tablets administered with the same schedule of Propranolol tablets

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative Sensory Testing (QST)
Description: Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST)
Description: Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychometric assessment
Description: Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
Study: NCT02518750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: Given IT as ITMHA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Description: Given intrathecally (IT) or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO at consistent time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Description: Given IT or IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II.
Study: NCT00001721

Intervention type: DRUG
Intervention: CRH

Intervention type: DRUG
Intervention: Cholesterol